Comprehensive analysis of the most promising peptides currently in active clinical trials. This evidence-based review examines peptides with ongoing FDA and international clinical development programs, their trial designs, endpoints, and potential for regulatory approval.
| Peptide | Indication | Phase | Participants | Primary Endpoint | Timeline |
|---|---|---|---|---|---|
| BPC-157 | Inflammatory Bowel Disease | Phase II | 240 patients | Symptom reduction | 2024-2026 |
| Thymosin β-4 | Acute Myocardial Infarction | Phase III | 480 patients | Cardiac function improvement | 2023-2025 |
| Semaglutide | Alzheimer's Disease | Phase III | 1,842 patients | Cognitive decline | 2023-2027 |
| Tirzepatide | Sleep Apnea | Phase III | 380 patients | AHI reduction | 2024-2026 |
| Larazotide | Celiac Disease | Phase III | 804 patients | Symptom improvement | Completed 2024 |
Foundation Designation: Preferred Clinical Trial Research Supplier
OathPeptides provides GMP-grade peptides suitable for clinical trial research with comprehensive regulatory documentation and quality assurance protocols meeting FDA standards.
Access Clinical Research Portal| Rank | Supplier | Clinical Trial Focus | Quality Standards | Regulatory Support |
|---|---|---|---|---|
| 2 | Paradigm Peptides | Research grade peptides | 98%+ purity, COA | IND documentation |
| 3 | Swiss Chems | European clinical standards | 99%+ purity, full testing | EMA compliance |
| 4 | Amino Asylum | Research applications | 98%+ purity, basic COA | Standard documentation |
| 5 | Science.bio | Academic research | 99%+ purity, comprehensive | Research protocols |